Literature DB >> 8389245

p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes.

A Marchetti1, F Buttitta, G Merlo, F Diella, S Pellegrini, S Pepe, P Macchiarini, A Chella, C A Angeletti, R Callahan.   

Abstract

Alterations of p53 are one of the most common molecular changes found in all types of lung tumors, suggesting a crucial role for p53 in bronchial carcinogenesis. However, the prognostic significance of p53 abnormalities in lung cancer patients is still unclear. By using genetic and immunohistochemical methods we have found p53 alterations in 40 of 53 (75%) primary, resected non-small cell lung cancer. A strong association (P = 0.0015) was found between deletions on chromosome region 17p13.3 and p53 mutations suggesting that loss of the wild-type p53 allele might be necessary for tumorigenesis. Correlations to clinicopathological parameters showed that p53 alterations (structural aberration of the gene and/or nuclear accumulation of the protein) are significantly linked with metastatic involvement of hilar and mediastinal lymph nodes (P < 0.01). Since the latter are well established prognostic factors for non-small cell lung cancer, p53 aberrations may also be a predictor of tumor aggressiveness.

Entities:  

Mesh:

Year:  1993        PMID: 8389245

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  P53 expression in stage I squamous cell lung cancer.

Authors:  J Moldvay; J Strausz; M Egerváry; L Agócs; J Bocsi; Z Schaff
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

2.  Antiproliferative and apoptotic activities of ketonucleosides and keto-C-glycosides against non-small-cell lung cancer cells with intrinsic drug resistance.

Authors:  J Paterson; C Uriel; M J Egron; J Herscovici; K Antonakis; M A Alaoui-Jamali
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  Clinical importance of correlations between p53 immunoreactivity and clinicopathological parameters in lung carcinoma.

Authors:  B A Dursun; L Memiş; A Dursun; H Bayiz; M Ozkul
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

4.  Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors.

Authors:  E Brambilla; A Negoescu; S Gazzeri; S Lantuejoul; D Moro; C Brambilla; J L Coll
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

5.  Investigation of c-myc and p53 gene alterations in the tumor and surgical borderline tissues of NSCLC and effects on clinicopathologic behavior: by the FISH technique.

Authors:  T Yakut; U Egeli; C Gebitekin
Journal:  Lung       Date:  2003       Impact factor: 2.584

6.  p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma.

Authors:  S Bosari; G Viale; M Roncalli; D Graziani; G Borsani; A K Lee; G Coggi
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

Review 7.  The clinical significance of p53 aberrations in human tumours.

Authors:  S Bosari; G Viale
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

8.  Carcinosarcoma of the colon: report of a case with morphological, ultrastructural and molecular analysis.

Authors:  Andrea Ambrosini-Spaltro; Valentina Vaira; Paola Braidotti; Marco P L Rovati; Stefano Ferrero; Silvano Bosari
Journal:  BMC Cancer       Date:  2006-07-12       Impact factor: 4.430

9.  Evaluation of FHIT gene alterations in ovarian cancer.

Authors:  F Buttitta; A Marchetti; O Radi; G Bertacca; S Pellegrini; A Gadducci; A R Genazzani; G Bevilacqua
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

10.  p53 protein is absent from the serum of patients with lung cancer.

Authors:  M A Levesque; M D'Costa; E P Diamandis
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.